Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06627413
PHASE1

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Sponsor: Intra-Cellular Therapies, Inc.

View on ClinicalTrials.gov

Summary

Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.

Official title: A Phase 1b, Open-label Study to Determine the Pharmacokinetics, Safety, and Tolerability of Single, Ascending Doses of Lumateperone Long-acting Injectable Formulations Administered Intramuscularly to Patients With Schizophrenia or Schizoaffective Disorder

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

52

Start Date

2024-08-23

Completion Date

2025-11-20

Last Updated

2026-07-31

Healthy Volunteers

No

Interventions

DRUG

Lumateperone Capsule

Lumateperone 42 mg capsule, oral administration

DRUG

Lumateperone LAI

Lumateperone LAI X500-E2 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-E3 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-X2 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI X500-X5 IM injection

DRUG

Lumateperone LAI

Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Locations (4)

Collaborative Neuroscience Research, LLC

Los Alamitos, California, United States

CenExeli Research LLC

Atlanta, Georgia, United States

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Hassman Research Institute, LLC.

Marlton, New Jersey, United States